This Article Full Text Full Text (PDF) All Versions of this Article: 36/8/1808    most recent 01.STR.0000173403.60553.27v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisher, M. Search for Related Content PubMed PubMed Citation Articles by Fisher, M. Related Collections Neuroprotectors Thrombolysis Acute Cerebral Infarction

(Stroke. 2005;36:1808.)
© 2005 American Heart Association, Inc.

Comments, Opinions, and Reviews

Enhancing the Development and Approval of Acute Stroke Therapies

Stroke Therapy Academic Industry Roundtable

Marc Fisher, MD for the Stroke Therapy Academic Industry Roundtable IV

From the UMass/Memorial Healthcare Center, Worcester, Mass.

Correspondence to Marc Fisher, MD, UMass/Memorial Healthcare Center, 119 Belmont St, Worcester, MA 01605. E-mail fisherm{at}ummhc.org

Background— Previous Stroke Therapy Academic Industry Roundtable (STAIR) meetings focused on preclinical evidence of drug efficacy and enhancing acute stroke trial design and performance. A fourth (STAIR-IV) was held to discuss relevant issues related to acute stroke drug development and regulatory approval.

Summary of Review— The STAIR-IV meeting had 3 main focus areas. The first topic was novel approaches to statistical design of acute stroke trials and appropriate outcome measures. The second focus was the need for better cooperation among participants in stroke therapy development that may be addressed through a national consortium of stroke trial centers in the United States and elsewhere. Lastly, regulatory issues related to the approval of novel mono and multiple acute stroke therapies were discussed.

Conclusions— The development of additional acute stroke therapies represents a large unmet need with many remaining challenges and also opportunities to incorporate novel approaches to clinical trial design that will lead to regulatory approval. The STAIR-IV meeting explored new concepts of trial methodology and data analysis, initiatives for implementing a US clinical trialist consortium, and pertinent regulatory issues to expedite approval of novel therapies.

Key Words: ischemia • stroke, acute

This article has been cited by other articles:

				H.-C. Diener, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, A. Shuaib, T. Ashwood, W. Wasiewski, V. Alderfer, et al. NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials Stroke, June 1, 2008; 39(6): 1751 - 1758. [Abstract] [Full Text] [PDF]

				G. A. Donnan The 2007 Feinberg Lecture: A New Road Map for Neuroprotection Stroke, January 1, 2008; 39(1): 242 - 242. [Abstract] [Full Text] [PDF]

				J. L. Saver Clinical Impact of NXY-059 Demonstrated in the SAINT I Trial: Derivation of Number Needed to Treat for Benefit Over Entire Range of Functional Disability Stroke, May 1, 2007; 38(5): 1515 - 1518. [Abstract] [Full Text] [PDF]

				R. Delgado-Mederos, A. Rovira, J. Alvarez-Sabin, M. Ribo, J. Munuera, M. Rubiera, E. Santamarina, O. Maisterra, P. Delgado, J. Montaner, et al. Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke Stroke, March 1, 2007; 38(3): 955 - 960. [Abstract] [Full Text] [PDF]

				M. P. Goldberg New Approaches to Clinical Trials in Neuroprotection: Introduction Stroke, February 1, 2007; 38(2): 789 - 790. [Full Text] [PDF]

				M. Fisher, D. F. Hanley, G. Howard, E. C. Jauch, S. Warach, and for the STAIR Group Recommendations From the STAIR V Meeting on Acute Stroke Trials, Technology and Outcomes Stroke, February 1, 2007; 38(2): 245 - 248. [Full Text] [PDF]

				K. R. Lees, A. Davalos, S. M. Davis, H.-C. Diener, J. Grotta, P. Lyden, A. Shuaib, T. Ashwood, H.-G. Hardemark, W. Wasiewski, et al. Additional Outcomes and Subgroup Analyses of NXY-059 for Acute Ischemic Stroke in the SAINT I Trial Stroke, December 1, 2006; 37(12): 2970 - 2978. [Abstract] [Full Text] [PDF]